Research journal · Tirzepatide
SURMOUNT-1: Tirzepatide for Weight Management
Released: · Last reviewed:
The pivotal weight-management trial for the approved tirzepatide product.
SURMOUNT-1 is the pivotal weight-management trial most often cited for tirzepatide, and the source of the "up to ~20%+ weight loss" figures that appear in marketing. This summary describes its widely reported design and outcomes and the limits on applying them to compounded products.
Why this study matters
Tirzepatide acts on two receptor systems (GLP-1 and GIP) rather than one, and SURMOUNT-1 is the trial most cited for the claim that it produces greater average weight loss than semaglutide alone. The reported dose-dependent outcomes are the basis for tirzepatide's premium positioning — and its higher price floor in the compounded market.
Design, as widely reported
SURMOUNT-1 was a randomized, double-blind, placebo-controlled trial of once-weekly subcutaneous tirzepatide at multiple dose levels versus placebo, with lifestyle intervention, in adults with obesity or overweight without diabetes, over 72 weeks, with change in body weight as the central focus. Exact design details and statistics will be confirmed at review.
Reported outcomes
FDA-approved injectable products at studied doses. These outcomes do not transfer to compounded, microdose, or oral/sublingual formulations. Values pending citation confirmation at medical review.
View chart data as a table
| Trial & product | Mean weight reduction | Duration |
|---|---|---|
| SURMOUNT-1 — 15 mg (reported mean) | 20.9% | 72 weeks |
| SURMOUNT-1 — 10 mg (reported mean) | 19.5% | 72 weeks |
The widely reported headline is a dose-dependent mean total body-weight reduction reaching roughly 20%+ at the highest studied dose over 72 weeks. As with semaglutide, these figures belong to the approved injectable product at studied doses and are the benchmark against which compounded-product claims should be read skeptically. At 15 mg the mean reduction was 20.9% under the treatment-regimen estimand (22.5% under the efficacy estimand, which assumes participants stayed on treatment); the 20.9% figure is the one this site uses.
Why it doesn't transfer
The same limits apply as for semaglutide: the result establishes what approved injectable tirzepatide does at studied doses, not what a compounded preparation, a microdose, or an oral product achieves. There is no FDA-approved oral tirzepatide at all, which makes oral compounded tirzepatide claims particularly unmoored from any approved-product analogue.
Practical interpretation
Use the reported figures as the approved-product benchmark, and treat compounded tirzepatide's expected outcome as uncertain absent formulation-specific evidence. The higher captured price floor for compounded tirzepatide versus semaglutide reflects the more expensive active ingredient, not a guarantee of the trial outcomes in a compounded form.
Summary pending medical review and citation confirmation. Not medical advice. Describes an FDA-approved product; compounded products are not FDA approved and their outcomes are not established by this trial.